Over the next 48 weeks, those who stopped taking semaglutide regained almost 6.9% of their body weight
One study of the GLP-1 raising effects of the Mediterranean diet demonstrated a peak GLP-1 level of approximately 59 picograms per millilitre of blood serum
Several cardiovascular outcome trials (CVOTs) have also reported that GLP-1 RAs may be associated with mitigating kidney-related outcomes, including albuminuria, decline in eGFR and the risk of end-stage kidney disease, independent of their effects on glycemic control 14,15,17,26,27
These findings highlight the intricate interplay between gut bacteria and GLP-1 regulation, further emphasizing the need for continued exploration in this area to elucidate the full spectrum of microbial influences on metabolic pathways
The efficacy and safety of fixed combination of basal insulin and a GLP-1 RA will be reviewed